Literature DB >> 31368112

Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.

Suthesh Sivapalaratnam1,2,3, Lisa Linpower1, Bala Sirigireddy1, Alexandra Agapidou1, Susan Jain4, Nay Win5, Dimitris A Tsitsikas1.   

Abstract

Entities:  

Keywords:  haemolysis; sickle cell disease; transfusion medicine

Mesh：

Substances：

Year:  2019        PMID： 31368112     DOI： 10.1111/bjh.16103

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Red cell transfusion and alloimmunization in sickle cell disease.

Authors:  Grace E Linder; Stella T Chou
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

2.  Hyperhemolysis in the Setting of Mixed-Autoimmune Hemolytic Anemia: A Rare Complication of COVID-19.

Authors:  Sonya Narula; Sean Winkle; Kenneth Brand; Farhan Shah; Priscilla Fujikawa; Tyler Truitt; Mark Currie
Journal:  Cureus       Date:  2021-12-12

3.  Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab.

Authors:  Christine Fuja; Vishesh Kothary; Timothy Clifford Carll; Savita Singh; Paul Mansfield; Geoffrey D Wool
Journal:  Transfusion       Date:  2022-05-30       Impact factor: 3.337

4.  Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.

Authors:  Sasmith R Menakuru; Adelina Priscu; Vijaypal Dhillon; Ahmed Salih
Journal:  Hematol Rep       Date:  2022-07-21

Review 5.  Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.

Authors:  Anazoeze Jude Madu; Angela Ogechukwu Ugwu; Chilota Efobi
Journal:  Med Princ Pract       Date:  2020-11-11       Impact factor: 1.927
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.